<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">urmj</journal-id><journal-title-group><journal-title xml:lang="ru">Уральский медицинский журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Ural Medical Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2949-4389</issn><publisher><publisher-name>Ural State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.25694/URMJ.2018.03.030</article-id><article-id custom-type="elpub" pub-id-type="custom">urmj-557</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КАРДИОЛОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CARDIOLOGY</subject></subj-group></article-categories><title-group><article-title>Дополнительные критерии стратификации риска ишемического инсульта у пациентов с фибрилляцией предсердий и одним не связанным с полом баллом по шкале CHA2DS2-VASс обусловленным артеиальной гипертонией</article-title><trans-title-group xml:lang="en"><trans-title>Additional criteria for stratifying the ischemic stroke risk in patients with atrial fibrillation and one non-sex-related score on the CHA2DS2-VASC scale due to arterial hypertension</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Николин</surname><given-names>Денис Юрьевич</given-names></name><name name-style="western" xml:lang="en"><surname>Nicolin</surname><given-names>D. Y.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фокина</surname><given-names>Елена Георгиевна</given-names></name><name name-style="western" xml:lang="en"><surname>Fokina</surname><given-names>E. G.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Грачев</surname><given-names>Вадим Геннадьевич</given-names></name><name name-style="western" xml:lang="en"><surname>Grachev</surname><given-names>V. G.</given-names></name></name-alternatives><email xlink:type="simple">grach_vad@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Липченко</surname><given-names>Александр Анатольевич</given-names></name><name name-style="western" xml:lang="en"><surname>Lipchenko</surname><given-names>A. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Архипов</surname><given-names>Михаил Викторович</given-names></name><name name-style="western" xml:lang="en"><surname>Arkhipov</surname><given-names>M. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>ООО Медицинское объединение «Новая больница»</institution><country>Russian Federation</country></aff><aff xml:lang="ru" id="aff-2"><institution>ФГБОУ ВО «Уральский государственный медицинский университет»</institution><country>Russian Federation</country></aff><aff xml:lang="ru" id="aff-3"><institution>ФГБОУ ВО «Уральский государственный медицинский университет» Минздрава России</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>14</day><month>04</month><year>2021</year></pub-date><volume>0</volume><issue>3</issue><fpage>5</fpage><lpage>11</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Николин Д.Ю., Фокина Е.Г., Грачев В.Г., Липченко А.А., Архипов М.В., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Николин Д.Ю., Фокина Е.Г., Грачев В.Г., Липченко А.А., Архипов М.В.</copyright-holder><copyright-holder xml:lang="en">Nicolin D.Y., Fokina E.G., Grachev V.G., Lipchenko A.A., Arkhipov M.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.umjusmu.ru/jour/article/view/557">https://www.umjusmu.ru/jour/article/view/557</self-uri><abstract><p>Цель. Выявление не входящих в шкалу CHA2DS2-VASc характеристик, влияющих на риск ишемического инсульта у пациентов с фибрилляцией предсердий (ФП) и одним не связанным с половой принадлежностью фактором риска (ФР) тромбоэмболических осложнений по этой шкале, обусловленным артериальной гипертонией (АГ) Материалы и методы. Проведено исследование «случай-контроль» по данным ретроспективного анализа историй болезни пациентов с ФП. основную группу составили госпитализированные в связи с развитием ишемического инсульта пациенты с неклапанной ФП и одним дополнительным к полу ФР по шкале CHA2DS2-VASc, обусловленным АГ, в период, предшествовавший развитию инсульта. В качестве группы сравнения подобраны сопоставимые по демографическим характеристикам пациенты с неклапанной ФП с одним дополнительным к полу ФР по шкале CHA2DS2-VASc, обусловленным АГ, не переносившие инсультов и системных эмболий. анализировались данные анамнеза, результаты электрокардиографического исследования, эхокардиографического исследования (ЭхокГ) и ультразвукового дуплексного сканирования артерий брахиоцефальной зоны (УЗдС БЦА). результаты. В основную группу включены 37 пациентов, возраст 60,15 (±6,21) лет, 27 % женщин, в группу сравнения -48 пациентов, возраст 60,13 (±4,85) лет, 37,58 % женщин. У пациентов основной группы по сравнению с пациентами группы сравнения достоверно чаще выявлялись постоянная форма ФП (48,65% и 14,58 %, р = 0,001), признаки гипертрофии левого желудочка (ГЛЖ) по данным ЭхоКГ (67,6 % и 43,6 %, р = 0,026) и утолщение комплекса интима-медиа (КИМ) по данным УЗДС БЦА &gt;0,9 мм (73 % и 25%, р &lt;0,0001). При однофакторном анализе выявлено значимое увеличение риска ишемического инсульта при наличии постоянной формы ФП (отношение шансов (ОШ) 5,28, 95 % доверительный интервал (ДИ) 1,88 - 14,80), ГЛЖ по данным ЭхоКГ (ОШ 2,81, 95 % ДИ 1,15 - 6,91) и утолщения КИМ (ОШ 7,88, 95 % ДИ 2,96 - 20,94). Заключение. При оценке риска ишемического инсульта и решении вопроса о назначении оральных антикоагулянтов пациентам с ФП и одним дополнительным к полу Фр, обусловленным АГ, по шкале CHA2DS2-VASc, у которых показания для антикоагулянтной терапии не носят абсолютного характера, целесообразно учитывать данные ЭхоКГ, УЗДС БЦА и форму ФП.</p></abstract><trans-abstract xml:lang="en"><p>Purpose. Identification of characteristics, not included in the CHA2DS2-VASc scale, affecting the risk of ischemic stroke in patients with atrial fibrillation (AF) and one non-sex-related risk factor (RF), due to arterial hypertension (AH), of thromboembolic events on this scale. Methods. A “case-control” study was conducted according to retrospective analysis of medical records of patients with AF. The main group included hospitalized due to development of ischemic stroke patients with non-valvular AF and single additional to gender RF on the CHA2DS2-VASc scale due to AH in the period prior to the stroke development. As a comparison group, patients with comparable demographic characteristics, having non-valvular AF with single additional to gender RF on the CHA2DS2-VASc scale due to AH and no history of stroke or systemic embolism, were selected. Anamnesis data and the results of electrocardiography, echocardiography and ultrasonic duplex scanning of brachiocephalic arteries were analyzed. Results. The main group included 37 patients, age 60.15 (±6,21) years, 27% women. The control group included 88 patients, age 60.13 (±4,85) years, 37.58% women. Patients of the main group, compared to the control group patients, significantly more often showed permanent AF (48.7% and 14.3%, p = 0.01), signs of left ventricular hypertrophy (LVH) according to echocardiography (67.6% and 43.6% , p = 0.026), and thickening of the intima-media complex (cIMT) &gt; 0.9 mm (73% and 25%, p &lt;0.0001) according to ultrasonic duplex brachiocephalic arteries scanning. The univariate analysis showed a significant increase of ischemic stroke risk in the presence of a permanent AF (odds ratio (OR) 5.28; 95% confidence interval (CI) 1,15 - 6,94), LVH according to echocardiography (OR 2.81, 95% CI 1.15 - 6.91) and cIMT thickening (OR 7.88, 95% CI 2.96 - 20.94). Conclusion. When assessing the risk of ischemic stroke and making the decision on the oral anticoagulants appointment in patients with atrial fibrillation and single additional to gender risk factor on the CHA2DS2-VASc scale due to AH, in which the indications for anticoagulant therapy are not absolute, it is advisable to consider the data of echocardiography, ultrasonic duplex scanning of brachiocephalic arteries and the form of AF.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>фибрилляция предсердий</kwd><kwd>инсульт</kwd><kwd>стратификация риска</kwd><kwd>atrial fibrillation</kwd><kwd>stroke</kwd><kwd>risk assessment</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Kirchhof P., Benussi S., Kotecha D., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37 (38): 2893-2962.</mixed-citation><mixed-citation xml:lang="en">Kirchhof P., Benussi S., Kotecha D., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37 (38): 2893-2962.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Lip G., Flemming S., Rasmussen L.H. Oral Anticoagulation, Aspirin, or No Therapy in Patients With Nonvalvular AF With 0 or 1 Stroke Risk Factor Based on the CHA2DS2-VASc Score. J Am Coll Cardiol. 2015; 65 (14): 1385-1394.</mixed-citation><mixed-citation xml:lang="en">Lip G., Flemming S., Rasmussen L.H. Oral Anticoagulation, Aspirin, or No Therapy in Patients With Nonvalvular AF With 0 or 1 Stroke Risk Factor Based on the CHA2DS2-VASc Score. J Am Coll Cardiol. 2015; 65 (14): 1385-1394.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Бритов А.Н., Поздняков Ю.М., Волкова Е.Г., и др. Национальные рекомендации по кардиоваскулярной профилактике. Кардиоваскулярная терапия и профилактика 2011, 6, приложение 2:1-64. ISSN 17288800.</mixed-citation><mixed-citation xml:lang="en">Бритов А.Н., Поздняков Ю.М., Волкова Е.Г., и др. Национальные рекомендации по кардиоваскулярной профилактике. Кардиоваскулярная терапия и профилактика 2011, 6, приложение 2:1-64. ISSN 17288800.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Lang RM, Bierig M., Devereux R.B., et al. Recommendations for chamber quantification. Eur J Echocardiography. 2006 Mar; 7(2):79-108.</mixed-citation><mixed-citation xml:lang="en">Lang RM, Bierig M., Devereux R.B., et al. Recommendations for chamber quantification. Eur J Echocardiography. 2006 Mar; 7(2):79-108.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Mancia G., Fagard R., Narkiewicz K. et al. Рекомендации по лечению артериальной гипертонии ESH/ESC 2013. Российский кардиологический журнал 2014, 1 (105): 7-94.</mixed-citation><mixed-citation xml:lang="en">Mancia G., Fagard R., Narkiewicz K. et al. Рекомендации по лечению артериальной гипертонии ESH/ESC 2013. Российский кардиологический журнал 2014, 1 (105): 7-94.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Goette A., Kalman J.M., Aguinaga L. et al. EHRA/ HRS/APHRS/SOLAECE expert consensus on Atrial cardiomyopathies: Definition, characterisation, and clinical implication. J Arrhythm. 2016 Aug; 32(4):247-78.</mixed-citation><mixed-citation xml:lang="en">Goette A., Kalman J.M., Aguinaga L. et al. EHRA/ HRS/APHRS/SOLAECE expert consensus on Atrial cardiomyopathies: Definition, characterisation, and clinical implication. J Arrhythm. 2016 Aug; 32(4):247-78.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Savino J.A., Halperin J.L. Should patient with atrial fibrillation and 1 stroke risk factor (CHA2DS2-VASc score 1 in men, 2 in women) be anticoagulated? The CHA2DS2-VASc 1 conundrum: decision making at the lower end of the risk spectrum. Circulation. 2016 Apr 12; 133(15): 1504-1511.</mixed-citation><mixed-citation xml:lang="en">Savino J.A., Halperin J.L. Should patient with atrial fibrillation and 1 stroke risk factor (CHA2DS2-VASc score 1 in men, 2 in women) be anticoagulated? The CHA2DS2-VASc 1 conundrum: decision making at the lower end of the risk spectrum. Circulation. 2016 Apr 12; 133(15): 1504-1511.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Shadi Y., Boehme A.K., Hazan R. et al. Atrial Cardiopathy and Cryptogenic Stroke: A Cross-sectional Pilot Study J Stroke Cerebrovasc Dis. 2016 Jan; 25(1): 110-114.</mixed-citation><mixed-citation xml:lang="en">Shadi Y., Boehme A.K., Hazan R. et al. Atrial Cardiopathy and Cryptogenic Stroke: A Cross-sectional Pilot Study J Stroke Cerebrovasc Dis. 2016 Jan; 25(1): 110-114.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">King J.B., Azadani P.N., Suksaranjit P., et al. Left Atrial Fibrosis and Risk of Cerebrovascular and Cardiovascular Events in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2017 Sep 12; 70(11):1311-1321.</mixed-citation><mixed-citation xml:lang="en">King J.B., Azadani P.N., Suksaranjit P., et al. Left Atrial Fibrosis and Risk of Cerebrovascular and Cardiovascular Events in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2017 Sep 12; 70(11):1311-1321.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Apostolakis S., Sullivan R.M., Olshansky B., et al. Left ventricular geometry and outcomes in patients with atrial fibrillation: The AFFIRM Trial. Int J Cardiol. 2014 Jan 1; 170(3):303-308.</mixed-citation><mixed-citation xml:lang="en">Apostolakis S., Sullivan R.M., Olshansky B., et al. Left ventricular geometry and outcomes in patients with atrial fibrillation: The AFFIRM Trial. Int J Cardiol. 2014 Jan 1; 170(3):303-308.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Boyd A.C., McKay T., Nasibi S. et al. Left ventricular mass predicts left atrial appendage thrombus in persistent atrial fibrillation. Eur Heart J Cardiovasc Imaging. 2013 Mar; 14(3):269-75.</mixed-citation><mixed-citation xml:lang="en">Boyd A.C., McKay T., Nasibi S. et al. Left ventricular mass predicts left atrial appendage thrombus in persistent atrial fibrillation. Eur Heart J Cardiovasc Imaging. 2013 Mar; 14(3):269-75.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Verdecchia P., Reboldi G., Di Pascuale G. et al. Prognostic usefulness of left ventricular hypertrophy by electrocardiography in patients with atrial fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study). Am J Cardiol. 2014 Feb 15;113(4):669-675</mixed-citation><mixed-citation xml:lang="en">Verdecchia P., Reboldi G., Di Pascuale G. et al. Prognostic usefulness of left ventricular hypertrophy by electrocardiography in patients with atrial fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study). Am J Cardiol. 2014 Feb 15;113(4):669-675</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Lorenz M.W., Markus H.S., Bots M.L. et al. Prediction of clinical cardiovascular events with carotid intimamedia thickness: A systematic review and meta-analysis. Circulation. 2007 Jan 30; 115(4):459-467.</mixed-citation><mixed-citation xml:lang="en">Lorenz M.W., Markus H.S., Bots M.L. et al. Prediction of clinical cardiovascular events with carotid intimamedia thickness: A systematic review and meta-analysis. Circulation. 2007 Jan 30; 115(4):459-467.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Bekwelem W., Jensen P.N., Norby F.L. et al. Carotid atherosclerosis and stroke in atrial fibrillation: The Atherosclerosis Risk in Communities Study. Stroke. 2016 Jun; 47(6):1643-1646.</mixed-citation><mixed-citation xml:lang="en">Bekwelem W., Jensen P.N., Norby F.L. et al. Carotid atherosclerosis and stroke in atrial fibrillation: The Atherosclerosis Risk in Communities Study. Stroke. 2016 Jun; 47(6):1643-1646.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Ganesan A.N., Chew D.P., Hartshorne T., et al. The impact of atrial fibrillation type on the risk of thromboembolism, mortality and bleeding: a systematic review and meta-analysis. Eur Heart J. 2016 May 21; 37(20):1591-1602.</mixed-citation><mixed-citation xml:lang="en">Ganesan A.N., Chew D.P., Hartshorne T., et al. The impact of atrial fibrillation type on the risk of thromboembolism, mortality and bleeding: a systematic review and meta-analysis. Eur Heart J. 2016 May 21; 37(20):1591-1602.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Steinberg B.A., Hellkamp A.S., Lokhnygina Y. et al. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial Eur Heart J. 2015 Feb 1; 36(5):288-96.</mixed-citation><mixed-citation xml:lang="en">Steinberg B.A., Hellkamp A.S., Lokhnygina Y. et al. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial Eur Heart J. 2015 Feb 1; 36(5):288-96.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Al-Khatib S.M., Thomas L., Wallentin L. et al. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. Eur Heart J. 2013 Aug; 34(31):2464-71.</mixed-citation><mixed-citation xml:lang="en">Al-Khatib S.M., Thomas L., Wallentin L. et al. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. Eur Heart J. 2013 Aug; 34(31):2464-71.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Сулимов В.А., Голицын С.П., Панченко Е.П., и др. Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА и АССХ. Российский кардиологический журнал 2013, 4 (Прил 3):5-100. ISSN 1560-4071.</mixed-citation><mixed-citation xml:lang="en">Сулимов В.А., Голицын С.П., Панченко Е.П., и др. Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА и АССХ. Российский кардиологический журнал 2013, 4 (Прил 3):5-100. ISSN 1560-4071.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
